Lodé, L., Ménard, A., Flet, L., Richebourg, S., Loirat, M., Eveillard, M., Le Bris, Y., Godon, C., Theisen, O., Gagez, A.-L., Cartron, G., Commes-Maerten, T., Villemagne, B., Luycx, O., Godmer, P., Pellat-Deceunynck, C., Soussi, T., Béné, M. C., Delaunay, J. and Peterlin, P. (2018) “Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide”, Haematologica. Pavia, Italy, 103(4), pp. e143-e146. doi: 10.3324/haematol.2017.181404.